Deborah H. Telman serves as the Executive Vice President, Corporate Affairs and General Counsel at Gilead Sciences, Inc., a leading biopharmaceutical company focused on developing innovative treatments for life-threatening diseases. In her role, Telman oversees the company's legal, compliance, and corporate affairs functions, playing a pivotal role in shaping Gilead's strategic direction and ensuring its adherence to regulatory standards. Her leadership has been instrumental in navigating complex legal landscapes and fostering strong relationships with stakeholders, which has contributed significantly to Gilead's growth and reputation in the industry. Before joining Gilead, Telman amassed extensive experience in the legal field, particularly in the life sciences sector. She previously held the position of Senior Vice President, General Counsel, and Corporate Secretary at Amylin Pharmaceuticals, where she was responsible for all legal matters, including intellectual property, litigation, and corporate governance. Her strategic legal guidance was crucial in facilitating Amylin's successful merger with Bristol-Myers Squibb in 2012. Telman's career also includes a significant tenure at the law firm of Cooley LLP, where she advised numerous biotechnology and pharmaceutical companies on a wide range of legal issues, from initial public offerings to mergers and acquisitions. Telman's achievements extend beyond her corporate roles; she is recognized as a thought leader in the legal and healthcare industries. She has been honored with several awards for her contributions to the field, including being named one of the "Top 25 General Counsels" by the San Francisco Business Times. Her commitment to advancing healthcare innovation and her adeptness at managing complex legal challenges have made her an invaluable asset to Gilead Sciences. Under her leadership, the company continues to thrive and make significant strides in improving patient outcomes worldwide.